Accéder au contenu
Merck

Growth Factors Do Not Improve Muscle Function in Young or Adult mdx Mice.

Biomedicines (2022-02-26)
Tue L Nielsen, Tessa M Hornsyld, Tomàs Pinós, Camilla Brolin, John Vissing, Thomas O Krag
RÉSUMÉ

Muscular dystrophies constitute a broad group of genetic disorders leading to muscle wasting. We have previously demonstrated that treating a muscular atrophy mouse model with growth factors resulted in increased muscle mass. In the present study, we treated the Duchenne mouse model mdx for 12 weeks with myogenic growth factors peri- and post-onset of muscular degeneration to explore the effects in the oxidative muscle soleus and the glycolytic muscle extensor digitorum longus (EDL). We found no overall beneficial effect in the peri-onset group at the conclusion of the study. In the post-onset group, the functional improvement by means of electrophysiological examinations ex vivo was mostly confined to the soleus. EDL benefitted from the treatment on a molecular level but did not improve functionally. Histopathology revealed signs of inflammation at the end of treatment. In conclusion, the growth factor cocktail failed to improve the mdx on a functional level.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
Anti-MYH1, (N-terminal) antibody produced in rabbit, affinity isolated antibody